Skip to main content
NVDA-0.33%AAPL-1.83%GOOGL+1.80%MSFT+2.39%AMZN+2.91%TSM-1.53%SPCX+1.71%META+0.71%AVGO+0.76%TSLA+2.35%SKHY-0.39%MU-0.94%BRK-B+0.75%LLY+0.02%AMD-1.47%JPM+0.36%WMT+0.62%V+2.24%XOM+0.55%ASMLa-1.84%JNJ+1.28%INTC-0.99%MA+1.76%0700.HK+3.26%ABBV+1.32%CSCO+1.96%1398.HK-0.92%CVX+0.61%COST-0.42%AMAT+0.05%AP2d-2.02%ORCL+4.71%LRCX-0.19%DELL+0.12%BAC+0.66%KO+0.21%CAT+0.64%PG+0.17%UNH+1.20%3988.HK+1.66%1816.HK+0.45%0005.HK+1.82%HSBA.L+1.10%GE+0.06%PM-0.28%0857.HK0.00%0939.HK+0.83%NFLX-0.99%MS+0.70%1288.HK-1.52%NZDMXN+1.44%USDMXN+1.37%EURAUD-0.85%AUDJPY+0.67%AUDCHF+0.63%EURUSD-0.54%EURZAR-0.48%AUDCAD+0.48%GBPAUD-0.45%CHFSEK+0.45%AUDNZD+0.44%EURGBP-0.44%USDTRY+0.44%USDPLN+0.43%AUDDKK+0.43%GBPTRY+0.41%EURNZD-0.41%EURCAD-0.37%USDSEK+0.33%AUDUSD+0.32%EURCNH-0.32%GBPHKD+0.32%GBPZAR-0.32%AUDSGD+0.32%EURCHF-0.32%USDJPY+0.31%USDZAR-0.30%GBPMXN-0.28%AUDNOK+0.28%EURJPY-0.26%NOKJPY+0.25%EURPLN+0.25%USDCHF+0.23%SGDJPY+0.22%GBPJPY+0.19%NZDJPY+0.19%CHFSGD+0.18%EURHKD-0.18%USDCAD+0.17%USDDKK+0.17%PLNJPY-0.16%USDILS+0.16%USDCNH-0.16%EURNOK-0.16%EURSEK+0.15%CHFNOK+0.14%GBPCHF+0.13%CADJPY+0.13%NZDSGD+0.12%NZDUSD-0.12%NZDCHF+0.12%EURSGD-0.12%GBPUSD-0.09%EURCZK+0.08%GBPCAD+0.08%CHFJPY+0.07%CADCHF+0.06%NZDCAD+0.06%USDSGD+0.06%GBPSGD+0.05%USDCOP-0.04%GBPNZD+0.02%USDNOK+0.02%USDHKD+0.01%USDTHB+0.01%EURDKK-0.01%C1-4.55%XAGUSD+2.99%GAGUSD+2.98%XPTUSD+2.73%XNGUSD+2.64%HG1+2.25%W1-1.94%GAUUSD+1.44%XAUUSD+1.44%S1-1.30%COTTON-0.69%COCOA+0.55%BTCUSD+1.40%ETHUSD+16.31%USDTUSD0.00%XRPUSD+8.70%SOLUSD+8.05%TRXUSDT+0.09%ZECUSDT+2.83%DOGEUSD+11.60%XMRUSDT-1.04%LINKUSD+12.58%XLMUSD+0.65%BCHUSDT+1.62%LTCUSD+5.93%UNIUSD+3.96%SUIUSD+2.02%HBARUSDT+1.06%TONUSD+24.22%TAOUSDT+2.82%AAVEUSD+2.83%DOTUSDT+9.65%ICPUSDT+5.13%ONDOUSDT+2.04%WLDUSDT+3.91%JUPUSDT+11.79%ARBUSDT+5.52%ATOMUSDT+14.63%STXUSDT+0.42%INJUSDT+2.75%FETUSDT+1.63%PYTHUSDT+5.21%SEIUSDT-0.89%TIAUSDT-5.29%IMXUSDT-0.22%GRTUSDT+2.86%OPUSDT+8.03%IOTAUSDT+1.18%WIFUSDT+2.61%AXSUSDT+0.99%POLUSDT+1.99%FARTCOINUSDT+0.05%EOSUSDT+3.17%DYDXUSDT+4.05%GALAUSDT+1.92%ORDIUSDT+0.84%RONINUSDT+1.08%NOTUSDT+3.72%NVDA-0.33%AAPL-1.83%GOOGL+1.80%MSFT+2.39%AMZN+2.91%TSM-1.53%SPCX+1.71%META+0.71%AVGO+0.76%TSLA+2.35%SKHY-0.39%MU-0.94%BRK-B+0.75%LLY+0.02%AMD-1.47%JPM+0.36%WMT+0.62%V+2.24%XOM+0.55%ASMLa-1.84%JNJ+1.28%INTC-0.99%MA+1.76%0700.HK+3.26%ABBV+1.32%CSCO+1.96%1398.HK-0.92%CVX+0.61%COST-0.42%AMAT+0.05%AP2d-2.02%ORCL+4.71%LRCX-0.19%DELL+0.12%BAC+0.66%KO+0.21%CAT+0.64%PG+0.17%UNH+1.20%3988.HK+1.66%1816.HK+0.45%0005.HK+1.82%HSBA.L+1.10%GE+0.06%PM-0.28%0857.HK0.00%0939.HK+0.83%NFLX-0.99%MS+0.70%1288.HK-1.52%NZDMXN+1.44%USDMXN+1.37%EURAUD-0.85%AUDJPY+0.67%AUDCHF+0.63%EURUSD-0.54%EURZAR-0.48%AUDCAD+0.48%GBPAUD-0.45%CHFSEK+0.45%AUDNZD+0.44%EURGBP-0.44%USDTRY+0.44%USDPLN+0.43%AUDDKK+0.43%GBPTRY+0.41%EURNZD-0.41%EURCAD-0.37%USDSEK+0.33%AUDUSD+0.32%EURCNH-0.32%GBPHKD+0.32%GBPZAR-0.32%AUDSGD+0.32%EURCHF-0.32%USDJPY+0.31%USDZAR-0.30%GBPMXN-0.28%AUDNOK+0.28%EURJPY-0.26%NOKJPY+0.25%EURPLN+0.25%USDCHF+0.23%SGDJPY+0.22%GBPJPY+0.19%NZDJPY+0.19%CHFSGD+0.18%EURHKD-0.18%USDCAD+0.17%USDDKK+0.17%PLNJPY-0.16%USDILS+0.16%USDCNH-0.16%EURNOK-0.16%EURSEK+0.15%CHFNOK+0.14%GBPCHF+0.13%CADJPY+0.13%NZDSGD+0.12%NZDUSD-0.12%NZDCHF+0.12%EURSGD-0.12%GBPUSD-0.09%EURCZK+0.08%GBPCAD+0.08%CHFJPY+0.07%CADCHF+0.06%NZDCAD+0.06%USDSGD+0.06%GBPSGD+0.05%USDCOP-0.04%GBPNZD+0.02%USDNOK+0.02%USDHKD+0.01%USDTHB+0.01%EURDKK-0.01%C1-4.55%XAGUSD+2.99%GAGUSD+2.98%XPTUSD+2.73%XNGUSD+2.64%HG1+2.25%W1-1.94%GAUUSD+1.44%XAUUSD+1.44%S1-1.30%COTTON-0.69%COCOA+0.55%BTCUSD+1.40%ETHUSD+16.31%USDTUSD0.00%XRPUSD+8.70%SOLUSD+8.05%TRXUSDT+0.09%ZECUSDT+2.83%DOGEUSD+11.60%XMRUSDT-1.04%LINKUSD+12.58%XLMUSD+0.65%BCHUSDT+1.62%LTCUSD+5.93%UNIUSD+3.96%SUIUSD+2.02%HBARUSDT+1.06%TONUSD+24.22%TAOUSDT+2.82%AAVEUSD+2.83%DOTUSDT+9.65%ICPUSDT+5.13%ONDOUSDT+2.04%WLDUSDT+3.91%JUPUSDT+11.79%ARBUSDT+5.52%ATOMUSDT+14.63%STXUSDT+0.42%INJUSDT+2.75%FETUSDT+1.63%PYTHUSDT+5.21%SEIUSDT-0.89%TIAUSDT-5.29%IMXUSDT-0.22%GRTUSDT+2.86%OPUSDT+8.03%IOTAUSDT+1.18%WIFUSDT+2.61%AXSUSDT+0.99%POLUSDT+1.99%FARTCOINUSDT+0.05%EOSUSDT+3.17%DYDXUSDT+4.05%GALAUSDT+1.92%ORDIUSDT+0.84%RONINUSDT+1.08%NOTUSDT+3.72%
GL

Glaukos Corporation (GKOS)

NYSE • Healthcare

$161.29
-$10.89 (-6.3%)
Market open

Last close at October 8, 2026 at 20:00 UTC

Open$170.67
Previous Close$161.29
Day Range$146.39 - $170.86
Avg. Volume (3M)996.1K
Market Cap$9.7B
52 Week Range
$73.16$191.62
Next EarningsIn 19 daysOct 28, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$185.6M100%
Gross Profitminus cost of goods$151.5M82%

In plain terms: out of every $100 in revenue, Glaukos Corporation currently loses $10.

Fundamentals & Financials

Revenue (TTM)
$612.8M
Net Income (TTM)
-$188M
EPS (TTM)
-$3.25
ROA (TTM)
-20.43%
Current Ratio
5.04

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-27.3%Q1 2026-$0.28
+40.0%Q2 2026-$0.18
+33.5%Q3 2026-$0.14
Next

Oct 28

in 19 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +33.5%

Glaukos beat expectations on both revenue and adjusted EPS in the second fiscal quarter of 2026, reported July 29, as revenue rose about 50% to about $185.6 million from about $124.1 million a year ago and beat the $150.9 million consensus by about 23%, while adjusted EPS of -$0.14 topped the -$0.21 estimate by about 34%. Gross margin came in near 82%, while operating margin was near -9% as operating income was negative about $17.3 million and net income was negative about $18.4 million, up about 7% from negative $19.7 million a year ago. Operating cash flow was about $14.8 million, and next-period consensus calls for EPS of -$0.16 on revenue of $156.0 million.

Next report — what to expect

Glaukos Corporation (GKOS) is set to report earnings on November 4, 2026. Wall Street expects EPS of -$0.095 on revenue of $167.9 million. For trailing context, revenue grew +49.5% year over year last quarter. GKOS has beaten EPS in 6 of 8 most recent quarters, making estimate comparisons a key focus.

View full earnings history

About Glaukos Corporation

Glaukos Corporation trades on the NYSE under GKOS and develops ophthalmic medical devices, centered on minimally invasive glaucoma products. Its FY2025 revenue was $507.4 million. The company sells iStent, iStent inject, and iStent inject W for use in cataract surgery and in treating mild-to-moderate open-angle glaucoma.

Name
Glaukos Corporation
CEO
Thomas William Burns
Website
www.glaukos.com
Industry
Healthcare
Year Founded
1998
Employees
1,094

Today's Snapshot

AI-generated

The session opened with GKOS 0.8% lower at 160.06, in line with a firmer sector. Glaukos announced positive Phase 4 results for iDose TR, a glaucoma implant used during cataract surgery.

Trading Volume

Below 10d avg (1.1M)

299.5K

vs S&P 500 Today

Outperforming Market

+0.77%

Updated: October 9, 2026 at 14:50 UTC

Technical Indicators

2 Buy3 Neutral3 Sell
GKOS presents a mixed, range-bound picture with a neutral overall stance. The security trades near 161.69, below several short- and medium-term averages but above the 100- and 200-day lines, while ADX around 19 indicates little directional conviction and momentum indicators are muted. Volatility is relatively elevated with ATR about 8.1, and on-balance volume shows recent distribution that offsets longer-term support. Together these signals balance short-term weakness against longer-term support, leaving technicals neither clearly bullish nor bearish. Technical takeaway: Neutral.
All signals
  • EMA (5 indicators)$138.50 - $164.99
    Sell
  • RSI (14)45.92
    Neutral
  • Stochastic %K (14, 3, 3)65.90
    Neutral
  • MACD Level (12, 26)-2.05
    Neutral

Peers & Related Assets

OCULOcular Therapeutix, Inc.
$7.51+3.9%
STAASTAAR Surgical Company
$22.38+0.1%
EYPTEyePoint Pharmaceuticals, Inc.
$3.46+4.2%
RXSTRxSight, Inc.
$4.85+1.0%
ALCAlcon Inc.
BLCOBausch + Lomb Corporation
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.